Markets

Zenas BioPharma To Present New Data From Phase 3 INDIGO Trial Evaluating Obexelimab In IgG4-RD At 6th International Symposium On IgG4-Related Disease, And ACR Convergence 2026

Sep 22, 2026 · 07:15 AM ET· updated 2h ago

– New data from the Phase 3 INDIGO open-label extension will include the longer-term flare protection and safety data of obexelimab in IgG4-RD –– Additional analyses will assess glucocorticoid-associated toxicity and

Why It Matters

Zenas BioPharma will show new test results for their medicine obexelimab. Investors watch to see if the medicine works safely over longer periods.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ZBIO32.40

-0.15 (-0.46%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.